A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration
Phase of Trial: Phase I/II
Latest Information Update: 19 Sep 2017
At a glance
- Drugs GB 102 (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADAGIO
- Sponsors GrayBug inc.
- 19 Sep 2017 According to a GrayBug inc. media release, the company has begun dosing patients in this trial.
- 24 Aug 2017 Status changed from not yet recruiting to recruiting.
- 10 Aug 2017 Status changed from planning to not yet recruiting.